176 related articles for article (PubMed ID: 37106214)
41. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
42. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
43. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Bachet JB; Wyrwicz L; Price T; Cremolini C; Phelip JM; Portales F; Ozet A; Cicin I; Atlan D; Becquart M; Vidot L; Mounedji N; Van Cutsem E; Taieb J; Falcone A
ESMO Open; 2020 Jun; 5(3):e000698. PubMed ID: 32487542
[TBL] [Abstract][Full Text] [Related]
44. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Napolitano S; Ciardiello D; De Falco V; Martini G; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Fazio N; Di Maio M; Del Tufo S; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
Int J Cancer; 2023 Oct; 153(8):1520-1528. PubMed ID: 37391938
[TBL] [Abstract][Full Text] [Related]
45. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP
BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060
[TBL] [Abstract][Full Text] [Related]
46. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
[TBL] [Abstract][Full Text] [Related]
47. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
[TBL] [Abstract][Full Text] [Related]
48. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
49. Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Zaniboni A; Barone CA; Banzi MC; Bergamo F; Blasi L; Bordonaro R; Bartolomeo MD; Costanzo FD; Frassineti GL; Garufi C; Giuliani F; Latiano TP; Martinelli E; Personeni N; Racca P; Tamburini E; Tonini G; Besse MG; Spione M; Falcone A
Future Oncol; 2021 Jun; 17(18):2315-2324. PubMed ID: 33663264
[TBL] [Abstract][Full Text] [Related]
50. Integrated safety summary for trifluridine/tipiracil (TAS-102).
Falcone A; Ohtsu A; Van Cutsem E; Mayer RJ; Buscaglia M; Bendell JC; Kopetz S; Bebeau P; Yoshino T
Anticancer Drugs; 2018 Jan; 29(1):89-96. PubMed ID: 29176395
[TBL] [Abstract][Full Text] [Related]
51. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
[TBL] [Abstract][Full Text] [Related]
52. Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer.
Kang C; Dhillon S; Deeks ED
Drugs; 2019 Sep; 79(14):1583-1590. PubMed ID: 31489588
[TBL] [Abstract][Full Text] [Related]
53. TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Borelli B; Crucitta S; Boccaccino A; Antista M; Antoniotti C; Marmorino F; Rossini D; Conca V; Germani MM; Provenzano L; Spagnoletti A; Leone AG; Cucchiara F; Pietrantonio F; Del Re M; Danesi R; Masi G; Cremolini C; Moretto R
Tumori; 2023 Oct; 109(5):481-489. PubMed ID: 36609197
[TBL] [Abstract][Full Text] [Related]
54. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
55. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
[TBL] [Abstract][Full Text] [Related]
56. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
Fernández Montes A; Carmona-Bayonas A; Jimenez-Fonseca P; Vázquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; De la Cámara Gómez J; Méndez JCM; Carriles Fernández C; Sanchez Cánovas M; Garcia García T
Sci Rep; 2021 Jul; 11(1):14321. PubMed ID: 34253805
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
[TBL] [Abstract][Full Text] [Related]
58. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
[TBL] [Abstract][Full Text] [Related]
59. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
[TBL] [Abstract][Full Text] [Related]
60. TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Roviello G; Fancelli S; Gatta Michelet MR; Aprile G; Nobili S; Roviello F; Cianchi F; Mini E; Lavacchi D
Crit Rev Oncol Hematol; 2020 Aug; 152():102987. PubMed ID: 32485527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
